
Solid Biosciences Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Solid Biosciences is a biotechnology company developing gene therapies for Duchenne muscular dystrophy and other neuromuscular and cardiac diseases. Its lead program, SGT-003, is a gene therapy candidate designed to deliver a micro-dystrophin construct to address the underlying genetic cause of Duchenne.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Brooks GabrielChief Medical Officer | Sell | $25K | 4,374at $5.62 | Oct 19, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SLDB activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.